Emerging inhaled bronchodilators: an update

M Cazzola - European Respiratory Journal, 2009 - Eur Respiratory Soc
Bronchodilators remain central to the symptomatic management of chronic obstructive
pulmonary disease and asthma, and, for this reason and also because the patent protection …

Emerging inhaled bronchodilators: an update

M Cazzola, MG Matera - European Respiratory Journal, 2009 - Eur Respiratory Soc
Bronchodilators remain central to the symptomatic management of chronic obstructive
pulmonary disease and asthma, and, for this reason and also because the patent protection …

[引用][C] Emerging inhaled bronchodilators: an update

M CAZZOLA, MG MATERA - The European respiratory journal, 2009 - pascal-francis.inist.fr
Emerging inhaled bronchodilators: an update CNRS Inist Pascal-Francis CNRS Pascal and
Francis Bibliographic Databases Simple search Advanced search Search by classification …

[引用][C] Emerging inhaled bronchodilators: an update

M Cazzola, MG Matera - EUROPEAN RESPIRATORY …, 2009 - iris.unicampania.it

Emerging inhaled bronchodilators: an update

M Cazzola, MG Matera - The European respiratory journal, 2009 - pubmed.ncbi.nlm.nih.gov
Bronchodilators remain central to the symptomatic management of chronic obstructive
pulmonary disease and asthma, and, for this reason and also because the patent protection …

Emerging inhaled bronchodilators: an update.

M Cazzola, MG Matera - The European Respiratory Journal, 2009 - europepmc.org
Bronchodilators remain central to the symptomatic management of chronic obstructive
pulmonary disease and asthma, and, for this reason and also because the patent protection …

[引用][C] Emerging inhaled bronchodilators: an update

M Cazzola, MG Matera - European Respiratory Journal, 2009 - cir.nii.ac.jp
Emerging inhaled bronchodilators: an update | CiNii Research CiNii 国立情報学研究所 学術
情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本を …

[PDF][PDF] Emerging inhaled bronchodilators: an update

M Cazzola, MG Matera - EUROPEAN RESPIRATORY JOURNAL, 2009 - Citeseer
Bronchodilators remain central to the symptomatic management of chronic obstructive
pulmonary disease and asthma, and, for this reason and also because the patent protection …